Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin in non-demented elderly with Alzheimer's disease neuropathology
jRCTs031210097Completed
- Sponsor
- Medilabo
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Rifampicin with Placebo (2 arms). Primary endpoint: Change in cerebrospinal fluid neurofilament light. Started Jun 2021; status: completed.
02
Drugs
rifampicin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCTs031210097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210097.